Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vandetanib in Children and Adolescents With Hereditary Medullary Thyroid Carcinoma
NCT00514046Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jul 2007
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vandetanib in medullary thyroid carcinoma (MTC), sponsored by National Cancer Institute. Started Jul 2007; status: completed.
02
Drugs
vandetanib
03
Conditions
medullary thyroid carcinoma (MTC)
Beyond the preview
Go deeper on NCT00514046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00514046.